Concentrix saw a positive improvement to its Relative Strength (RS) Rating on Monday, with an upgrade from 70 to 78.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary rating tracks market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the best-performing stocks often have an 80 or higher RS Rating in the early stages of their moves. See if Concentrix can continue to show renewed price strength and hit that benchmark.
Concentrix is working on a consolidation with a 66.00 buy point. See if the stock can break out in heavy volume.
While the company's top line growth fell last quarter from 10% to -1%, EPS grew 9%, up from -3% in the previous report.
Concentrix earns the No. 29 rank among its peers in the Computer Software-Enterprise industry group. Palantir Technologies, Nexxen International and ServiceNow are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
